More on Cepheid (CPHD) Q4 bottom line beats estimates as results were boosted by stronger sales...
More on Cepheid (CPHD) Q4 bottom line beats estimates as results were boosted by stronger sales and a $5.4M year-earlier charge related to the termination of a patent license. The company issues a downbeat outlook going forward however, projecting weaker-than-expected revenue for 2013. It now sees earnings of between $0.41 to $0.46 per shares on revenue of $375M to $385M. Street expectations were for $0.12 cents and $397M, respectively.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs